Solid Biosciences Inc. — Director's Dealing 2023

Feb 1, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Solid Biosciences Inc. (SLDB)
CIK: 0001707502
Period of Report: 2023-01-27

Reporting Person: Morris Carl Ashley (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-27	Common Stock	M	1233	—	Acquired	20201	Direct
2023-01-27	Common Stock	S	441	$7.49	Disposed	19760	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-27	Restricted Stock Units	$	M	1233	Disposed		Common Stock (1233)	Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: Includes 490 shares of common stock and 1,462 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2022 and November 30, 2022, respectively.

F3: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1).

F4: On January 27, 2022 (the "Grant Date"), the reporting person was granted 4,933 restricted stock units, vesting in four equal installments on the anniversary of the grant date.